Take a closer look at your untreated PD-L1 negative mNSCLC patients: meet Bill
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Could KEYTRUDA® (pembrolizumab) in combination with chemotherapy transform treatment expectations for your untreated PD-L1 metastatic
non-small cell lung cancer patients?*
Take a closer look at how KEYTRUDA in combination with chemotherapy could help your patients in the downloadable patient profile below.
PDF, 7.51 MB
Download Bill’s profile: 67-year-old male with stage IV non-squamous NSCLC, negative for EGFR and ALK mutations; PD-L1 non-expressor, no liver or brain metastases at diagnosis. Former smoker with a 10 pack-year history.
Find out more information about KEYTRUDA® (pembrolizumab) in metastatic NSCLC:
*KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.1
KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.1
- KEYTRUDA® (pembrolizumab) Summary of Product characteristics (SPC). 25mg/ml concentrate for infusion.
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website